Covaxin phase 3 trial data released: Jab shows 65.2% efficacy against Delta COVID-19 variant, says company

Covaxin  coronavirus vaccine has overall efficacy of 77.8 percent against symptomatic cases, while the indigenously developed jab showed an ...

Covaxin coronavirus vaccine has overall efficacy of 77.8 percent against symptomatic cases, while the indigenously developed jab showed an efficacy of 65.2 percent against the highly transmissible Delta variant of COVID-19, vaccine maker Bharat Biotech said citing the Phase 3 clinical trial data.

"Phase 3 clinical trials of Covaxin were an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the 2nd dose, conducted at 25 sites across India," the company's statement said.

The data, however, is yet to be peer-reviewed.

Labeling its research as "India's largest-ever COVID-19 vaccine trial", the company added that the overall efficacy figure was arrived at after 24 volunteers who were given the vaccine tested positive for COVID-19 out of a group of 130 confirmed cases.

The efficacy analysis of Covaxin also demonstrated the effectiveness of 93.4 percent against severely symptomatic COVID-19 infections, the company said. The safety analysis showed "that adverse events reported were similar to placebo, with 12 percent of the subjects experiencing commonly known side effects and less than 0.5 percent faced serious adverse events".

The company also claimed that the overall rate of adverse events observed "was lower than that seen in other COVID-19 vaccines".

On the other hand, the efficacy was 63.6 percent for patients who had asymptomatic COVID-19 infections. "Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission," the statement said.

Dr Krishna Ella, Bharat Biotech's chairman and managing director said, "The successful safety and efficacy readouts of COVAXIN® as a result of conducting the largest ever COVID Vaccines trials in India establishes the ability of India and developing world countries to focus towards innovation and novel product development. We are proud to state that Innovation from India will now be available to protect global populations."

Indian Council of Medical Research (ICMR) director-general Balram Bhargava echoed his Ella's statement.

He said, "I am delighted to note that Covaxin developed by ICMR and BBIL under an effective public private partnership, has demonstrated an overall efficacy of 77.8 percent in India’s largest COVID phase 3 clinical trial thus far. Our scientists at ICMR and BBIL have worked tirelessly to deliver a truly effective vaccine of highest international standards.

"Covaxin will not only benefit the Indian citizens but would also immensely contribute to protect the global community against the deadly SARS-CoV-2 virus. I am also pleased to see that COVAXIN® works well against all variant strains of SARS-CoV-2. The successful development of COVAXIN® has consolidated the position of Indian academia and Industry in the global arena."

Read Also
Name

Article,3,ASE News,2,BBC News - Technology,44,Business,23,codecanyon,3,DPR,1,Education / Employment,1,Entertainment,10,General knowledge,2,IANS – The Siasat Daily,8,IFTTT,49,India news,479,Latest news,1,Madhy Pradesh,465,main,19,National,162,News,1,PTI – The Siasat Daily,3,Sports,11,themeforest,1,World,22,World News,183,
ltr
item
India World News: Covaxin phase 3 trial data released: Jab shows 65.2% efficacy against Delta COVID-19 variant, says company
Covaxin phase 3 trial data released: Jab shows 65.2% efficacy against Delta COVID-19 variant, says company
India World News
https://www.asenews.page/2021/07/covaxin-phase-3-trial-data-released-jab.html
https://www.asenews.page/
https://www.asenews.page/
https://www.asenews.page/2021/07/covaxin-phase-3-trial-data-released-jab.html
true
8343353446356446311
UTF-8
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS PREMIUM CONTENT IS LOCKED STEP 1: Share to a social network STEP 2: Click the link on your social network Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy Table of Content